National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Economic evalution of glucosamine sulfate (Dona®) for the treatment of oestoarthritis in the Irish Healthcare setting.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
May 2009 June 2009 Reimbursement not recommended.

We do not believe that glucosamine sulfate (Dona®) is a cost effective therapy for the treatment of osteoarthritis in the Irish Healthcare setting.

Economic evaluation of glucosamine sulphate – summary